Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15695828
Butler B, Blystone SD (2005) Tyrosine phosphorylation of beta3 integrin provides a binding site for Pyk2. J Biol Chem 280, 14556-62 15695828
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, RGD increase
PP1 phorbol_ester, RGD inhibit treatment-induced increase
wortmannin phorbol_ester, RGD inhibit treatment-induced increase

Y773-p - ITGB3 (human)
Modsite: DtANNPLyKEAtstF SwissProt Entrez-Gene
Orthologous residues
ITGB3 (human): Y773‑p, ITGB3 (mouse): Y772‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Mn(2+) increase
vanadate increase
RGD increase
phorbol_ester RGD no effect upon treatment-induced increase
vitronectin increase
phorbol_ester no change compared to control
PP1 phorbol_ester decrease
wortmannin phorbol_ester decrease
calphostin_C phorbol_ester no change compared to control
Y27632 phorbol_ester decrease
piceatannol phorbol_ester decrease
phorbol_ester, RGD increase
PP1 phorbol_ester, RGD no effect upon treatment-induced increase
wortmannin phorbol_ester, RGD no effect upon treatment-induced increase
calphostin_C phorbol_ester, RGD no effect upon treatment-induced increase
Y27632 phorbol_ester, RGD no effect upon treatment-induced increase
piceatannol phorbol_ester, RGD inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Pyk2 (human) Induces phosphorylation sequence-specific competitor, co-immunoprecipitation

Y402-p - Pyk2 (human)
Modsite: CsIEsDIyAEIPDEt SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y402‑p, Pyk2 iso2 (human): Y402‑p, Pyk2 (mouse): Y402‑p, Pyk2 (rat): Y402‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) phospho-antibody, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RGD increase
phorbol_ester RGD augment treatment-induced increase
vitronectin increase
phorbol_ester vitronectin augment treatment-induced increase
phorbol_ester increase
vanadate phorbol_ester augment treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
wortmannin phorbol_ester inhibit treatment-induced increase
calphostin_C phorbol_ester no effect upon treatment-induced increase
Y27632 phorbol_ester inhibit treatment-induced increase
piceatannol phorbol_ester inhibit treatment-induced increase
vanadate no change compared to control
Mn(2+) no change compared to control
phorbol_ester, RGD increase
PP1 phorbol_ester, RGD inhibit treatment-induced increase
wortmannin phorbol_ester, RGD no effect upon treatment-induced increase
calphostin_C phorbol_ester, RGD no effect upon treatment-induced increase
Y27632 phorbol_ester, RGD no effect upon treatment-induced increase
piceatannol phorbol_ester, RGD no effect upon treatment-induced increase

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester, RGD increase
PP1 phorbol_ester, RGD inhibit treatment-induced increase
wortmannin phorbol_ester, RGD no effect upon treatment-induced increase